O Shaughnessy Asset Management LLC Increases Stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

O Shaughnessy Asset Management LLC boosted its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 260.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 248,844 shares of the company’s stock after purchasing an additional 179,866 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Dr. Reddy’s Laboratories were worth $3,929,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. EverSource Wealth Advisors LLC grew its holdings in shares of Dr. Reddy’s Laboratories by 423.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company’s stock valued at $29,000 after buying an additional 1,507 shares during the last quarter. POM Investment Strategies LLC lifted its position in Dr. Reddy’s Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock worth $36,000 after acquiring an additional 1,820 shares during the period. Farther Finance Advisors LLC grew its stake in Dr. Reddy’s Laboratories by 461.0% during the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company’s stock valued at $40,000 after purchasing an additional 2,093 shares during the last quarter. Allworth Financial LP increased its holdings in shares of Dr. Reddy’s Laboratories by 447.8% in the fourth quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock valued at $41,000 after purchasing an additional 2,230 shares during the period. Finally, Sierra Ocean LLC acquired a new stake in shares of Dr. Reddy’s Laboratories during the fourth quarter worth about $43,000. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Stock Performance

Shares of RDY stock opened at $13.25 on Thursday. The stock has a market cap of $11.06 billion, a PE ratio of 21.10 and a beta of 0.48. Dr. Reddy’s Laboratories Limited has a 52-week low of $12.50 and a 52-week high of $16.89. The business has a 50-day simple moving average of $13.38 and a 200-day simple moving average of $14.55. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, equities analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.